A naturalist's field notebook on the Epithalon and Epitalon literature

What Reviews Epitalon Is

Reviews Epitalon is a naturalist's field notebook kept on the peer-reviewed research literature for Epithalon and Epitalon — the synthetic tetrapeptide Ala-Glu-Asp-Gly, studied primarily as a telomerase activator and pineal-gland bioregulator.

It is a field notebook, not a practice: no one here diagnoses, treats, or prescribes; there is no clinic and no clinical staff; and nothing is manufactured, sold, or supplied. The writing is observation of published science, and every figure is cited.

The 'reviews' in the name is editorial framing: a site that reads and reviews the research record with the care and critical attention a naturalist brings to a field specimen. It is not a product-review site, not an aggregate of customer testimonials, and not a vendor directory. The modifier does not imply licensed medical reviewers or the evaluation of clinical outcomes in patients.

History of Epitalon Research: Khavinson and the St. Petersburg Institute

The Epithalon research record is rooted in one institution: the St. Petersburg Institute of Bioregulation and Gerontology, where Vladimir Khavinson and colleagues began studying Epithalamin (bovine pineal extract) in the 1970s. The synthetic tetrapeptide Epithalon — the four-amino-acid active fraction — was developed and characterized over the subsequent decades, with the telomerase-activation mechanism first formally described in 2003 ^[1].

Vladimir Nikolaevich Anisimov joined the longevity research strand in the early 2000s, contributing the rodent lifespan studies that remain the most-cited longevity data in the literature ^[3][4][14]. The melatonin normalization studies — in rhesus macaques and elderly human subjects — were conducted by Oleg Korkushko, Khavinson, and colleagues across 2001–2007 ^[5][6][7].

The most significant recent development is the 2025 study by Al-dulaimi, Thomas, Matta, and Roberts at Brunel University London, which independently confirmed dose-dependent telomere elongation in four human cell lines and identified divergent mechanisms by cell type ^[2]. This represents the first major external-institution replication of the central telomere claim — twenty-two years after the original Khavinson 2003 finding ^[1]. It is also the first confirmation published in a Western peer-reviewed journal by researchers with no institutional connection to the St. Petersburg group.

The single-group provenance limitation is acknowledged throughout this site. It is the most important caveat in the Epitalon literature, and a responsible reading of the record requires stating it plainly.

Editorial Standards

Every quantitative claim traces to a numbered citation in the references list, and the specific publication is cited rather than a secondary summary. Animal data is not carried over to human outcomes without the extrapolation being marked as such.

Where the evidence is strong, the notebook says so: the cell-line telomere elongation finding is reproduced and independently confirmed. Where it is limited, it says that too: human lifespan data does not exist, and the rodent longevity data comes primarily from one laboratory.

Nothing is prescribed. No doses are recommended. No products are evaluated. What was administered — to which species, at which dose, by which route, in which study — is described in the language of a careful field record, not a clinical leaflet.

The notebook holds no commercial relationship with any Epithalon or Epitalon supplier. It carries no affiliate links. It earns no revenue from the purchase of any compound.